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ABSTRACT
Monolaurin (also known as glycerol monolaurate) is a natural compound found
in coconut oil and is known for its protective biological activities as an antimicro-
bial agent. The nature of oral candidiasis and the increased antifungal resistance
demand the search for novel antifungal therapeutic agents. In this study, we
examine the antifungal activity of monolaurin againstCandida albicans biofilms (strain
ATCC:SC5314/MYA2876) in vitro and investigate whether monolaurin can alter gene
expression of host inflammatory cytokines, IL-1α and IL-1β. In a co-culture model,
oral fibroblast cells were cultured simultaneously withC. albicans for 24 hrs followed by
the exposure to treatments of monolaurin (3.9–2,500µM), positive control fluconazole
(32.2µM), and vehicle control group (1% ethanol), which was amodel used to evaluate
the cytotoxicity of monolaurin on fibroblasts as well as to analyze morphological
characteristics of biofilms through fluorescencemicroscopy. In addition, the co-culture
model was used for RNA extraction of oral fibroblasts to assess gene expression of
host inflammatory cytokines, using quantitative real-time PCR. Our results showed
the MIC and MFC of monolaurin were in the range 62.5–125 µM and 125–250 µM,
respectively. Biofilm antifungal assay showed significant reduction in Log (CFU/ml)
of biofilms treated with 1,250 and 2,500 µM of 1-monolaurin when compared to the
control groups . There was also a significant down-regulation of IL-1α and IL-1β in the
co-culture treatedwithmonolaurin. It can be concluded thatmonolaurin has a potential
antifungal activity againstC. albicans and canmodulate the pro-inflammatory response
of the host.
Subjects Cell Biology, Microbiology, Dentistry
Keywords Candida albicans, In vitro, Antimicrobial agent, Monolaurin, Biofilms, Virulence
factors, Proteolytic enzymes, Oral candidiasis, MIC/MFC, Host inflammatory response
INTRODUCTION
Candida albicans is a prevalent opportunistic human fungal pathogen that lives
commensally in the gut, oral pharyngeal, genito-urinary tract and skin. However, it may
become pathogenic in immunocompromised patients or in individuals with an imbalance
of competing bacterial microflora (Berman, 2012; Dovigo et al., 2011b; Neppelenbroek et al.,
2006). The disseminated forms of the disease can be life-threatening with mortality rates of
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40–60% among immunocompromised, cancer patients, or individuals exposed to multiple
treatments, such as broad spectrum antibiotics, chemotherapy, immunosuppressive
therapy, and anti-retroviral therapy (Dovigo et al., 2011a; Krcmery & Barnes, 2002;
Neppelenbroek et al., 2006). The pathogenicity of the Candida species is attributed to
critical virulence factors, such as adherence to surfaces (on both tissues and medical
devices), biofilm formation, evasion of host immune defense mechanisms, and secretion
of proteolytic enzymes, such as secreted aspartyl proteases (SAP) and phospholipases
(Correia et al., 2010).
As mentioned earlier, there are a number of virulence factors associated with the
pathogenicity of Candida albicans, such as biofilm formation and secretion of proteolytic
enzymes, e.g., secreted aspartic proteases (SAPs), phospholipase, and lipase enzymes.
Mature fungal biofilms are characterized by a dense community of both yeasts and hyphae
structures encased in a thick extracellular polymeric substance (EPS), which ensures
adequate diet is supplied to biofilms, transports waste products, and may also have a role
in the antifungal resistance of Candida species (Ramage et al., 2001). The gene expression
of SAPs (1–10) family as a whole has been associated with tissue damage and host invasion
of the pathogenic C. albicans (Lermann & Morschhauser, 2008; Nailis et al., 2010). Hyphal
formation is considered the most critical factor involved in epithelial invasion and the
degradation of epithelial cell junction proteins (Naglik et al., 2008; Villar et al., 2007).
Immune host defense plays a critical role in the phagocytosis of the pathogenic Candida
species during fungal infections. Activation of the CD4+ T cells results in the production of
pro-inflammatory chemokines and cytokines, such as IL-1α, IL-1β, and TNF-α. Antigen
uptake through activation of anti-inflammatory cytokines IL-10 via dendritic cells (DCs)
during the later phase of infection, ultimately leads to the elimination of the fungus
(Chandra et al., 2007; Gresnigt et al., 2012). Thus, the pathogenic state of candidiasis is
marked by an increase in the pro-inflammatory response, followed by an increase in the
anti-inflammatory cytokines.
Current treatments for C. albicans infection consist of topical and systemic
pharmaceutical antifungal agents, with triazoles being the first line of defense effective
against most Candida species (Samaranayake & Macfarlane, 1990). However, due to the
limited number of antifungal treatments available and the widespread use of such agents,
there has been an increase in antifungal resistance (Hunter et al., 1998; White, Marr &
Bowden, 1998). For instance, oropharyngeal candidiasis in patients with advanced HIV
infection and AIDS is usually treated with fluconazole. However, it is often difficult to
completely eradicate the infection without relapse occurring within a few months (Rex,
Rinaldi & Pfaller, 1995). Therefore, the increase in both fungal infections and antifungal
resistance demand the search for new and effective antifungal therapeutic agents.
Natural compounds present as potential antifungal agents, as they are readily available
in many foods and plants sources, and have been known in traditional medicine for
their antimicrobial, anti-inflammatory, and antioxidant effects (Martins et al., 2009).
Monolaurin is a monoglyceride, composed of lauric acid esterfied with glycerol, and is
found in coconut oil (Carpo, Verallo-Rowell & Kabara, 2007). It is important to note that
monolaurin is recognized as GRAS (Generally Recognized as Safe), as a food additive by the
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FDA (Food andDrugAdministration), with topical doses of up to 100mg/ml (Title 21, Code
of Federal Regulations, Part 184) (Peterson & Schlievert, 2006). Studies have shown that
monolaurin has broad bioactivities, such as antibacterial and antiviral properties (Bergsson
et al., 2001; Carpo, Verallo-Rowell & Kabara, 2007; Li et al., 2009; Peterson & Schlievert,
2006). In an in vitro study by Schlievert & Peterson (2012), the antibacterial activity of
glycerol monolaurate (GML) was tested against gram-positive bacteria, Staphylococcus
aureus. GML prevented biofilm formation of S. aureus with no drug resistance developing
at a sub-growth inhibitory concentration (Schlievert & Peterson, 2012). It was concluded
that GML has a broad-spectrum of antimicrobial activity and has the potential for future
application as a topical therapeutic agent in vivo. However, to the best of our knowledge, the
antifungal activity of monolaurin against Candida albicans biofilms has never been studied.
For the first time, this study aims to primarily evaluate the antifungal activity
of monolaurin against Candida albicans biofilms in vitro and to investigate whether
monolaurin can modulate host immune response during fungal infections. Furthermore,
we provide validation for the safety of monolaurin use in future in vivo study for the
treatment of oral candidiasis by assessing the cytotoxicity of monolaurin on oral fibroblast
cells. Finally, given the fact that proteolytic enzymes secreted by C. albicans are often
reported to elicit host tissue damage and are thus considered key virulence factors in the
pathogenicity of C. albicans, we examined whether monolaurin had any modulatory effects
on the enzymatic activities levels of proteinases and phospholipases enzymes.
MATERIALS & METHODS
Susceptibility test
The antifungal activity of 1-monolaurin (Sigma) was tested in vitro against the following
Candida albicans strains: fluconazole-resistant strain 96901, SC5314, ATCC: MYA2876,
and ATCC 90028, according to the NCCLS M27-A protocol (National Committee for
Clinical Laboratory Standards (NCCLS), 2002; Pasetto, Pardi & Murata, 2014). The strains
of C. albicans are proven virulent pathogens and were selected for their known genomic
sequencing (Jones et al., 2004). The minimum inhibitory concentration (MIC) was
determined using planktonicC. albicans inoculum of 5×103 CFU/ml, which was confirmed
using a spectrophotometer by measuring an absorbance in the range of 0.08–0.10 at
625 nm. C. albicans inoculum was grown in RPMI-1640 (Lonza) in a 96-well plate. Serial
dilutions in the range of 3.9–2,000 µM of 1-monolaurin (99.9% high-performance liquid
chromatography purchased from Sigma) were prepared. Based on the MIC found for
the tested C. albicans strains, fluconazole (32.2 µM) (Sigma) was used as the positive
control in this experiment in comparison to the vehicle control 1% Ethanol (v/v). The
plate was incubated for 24 h at 37 ◦C in 5% CO2. Minimum inhibitory concentration
(MIC) was determined after 24 h as the concentration, at which C. albicans growth was
visibly inhibited (National Committee for Clinical Laboratory Standards (NCCLS), 2002;
Pasetto, Pardi & Murata, 2014). Minimum fungicidal concentration (MFC) was found by
subculturing 20µl of each well on Sabouraud Dextrose Agar (BD). After 24 h of incubation,
MFC concentration was determined as the lowest concentration of 1-monolaurin, showing
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no visible C. albicans growth on the agar plates (National Committee for Clinical Laboratory
Standards (NCCLS), 2002; Pasetto, Pardi & Murata, 2014).
Biofilm assay
An inoculum of 1×106 CFU/ml of C. albicans (ATCC: SC5314/MYA2876) was grown for
24 h in a sterile 24-well plate using Yeast Nitrogen Base Medium (Difco) with 50 mM of
glucose for 24 h at 37 ◦C in 5%CO2 to establish initial biofilm growth. Total volume of 1ml
of inoculum was pipetted in each well. After 24 h of incubation, the biofilms were treated
once daily with 100 µl of 1-monolaurin at concentrations of 1,250 µM and 2,500 µM
(equivalent to 10×MIC and 20×MIC; respectively), which remained incubated with the
biofilms suspended in medium overnight. The vehicle control used was 1% ethanol while
the positive control was fluconazole (322µM; equivalent to ten times theMIC). Before each
treatment, biofilms were washed with Phosphate Buffer Solution (PBS) and replenished
with 900 µl of fresh medium in addition to 100 µl of the corresponding treatment, yielding
a total volume of 1 ml in each well. After 72 h of treatments, biofilms were suspended
in PBS and the solution was centrifuged at 10,000 rpm for 5 min (Santana et al., 2013).
Colony formation unit (CFU) was determined by suspending each sample of biofilm in 1
ml of PBS and plating 20 µl of the suspension on Sabouraud Dextrose Agar plates (BD).
After 24 h of incubation, the number of C. albicans colonies was counted and data was
expressed in Log (CFU/ml).
Proteinase and phospholipase enzyme secretion assay
Proteinase and phospholipase enzyme secretion assays were conducted as previously
performed by Santana et al. (2013). Biofilms of C. albicans were grown for 24 h in Yeast
Nitrogen Base Medium (Difco) with 50 mM of glucose at 37 ◦C in 5% CO2 and treated
using 1-monolaurin concentrations of 1,250 µM and 2,500 µM (10×MIC and 20×MIC;
respectively). Phospholipase A2 (for phospholipase assay) (Sigma) and Trypsin (for
proteinase assay) (Lonza) were used as standards. The vehicle control used in this assay was
1% ethanol. After 72 h of biofilm maturation, the enzyme secretion assays were performed
on biofilms suspended in PBS, which were sonicated for 15 s at 20% amplitude with pulses
at 5 s and 10 s intervals (FB120; Fischer Scientific, Pittsburgh, PA, USA). The proteinase
enzyme activity was determined by mixing the supernatant of the biofilm solution with
1% azocasein at 1:9 (v/v) for 1 h at 37 ◦C in 5% CO2. Then, 500 µl of 10% trichloroacetic
acid was added to stop the reaction. The solution was centrifuged for 5 min at 10,000
rpm and 500 µl of the supernatant was combined with 500 µl of NaOH, which was
incubated for 15 min at 37 ◦C in 5% CO2. Absorbance was read in a spectrophotometer at
440 nm (Goncalves et al., 2012; Pande et al., 2006; Santana et al., 2013). The phospholipase
enzyme activity was determined by mixing the supernatant of the biofilm solution with
phosphatidylcholine substrate for 1 h at 37 ◦C in 5% CO2 and reading the absorbance in a
spectrophotometer at 630 nm (Goncalves et al., 2012; Santana et al., 2013; Taniguchi et al.,
2009).
Seleem et al. (2016), PeerJ, DOI 10.7717/peerj.2148 4/17
Co-culture model fluorescence microscopy
Cytotoxicity assays using fluorometric quantification of cellular viability were performed
on oral fibroblast cells (ATCC: CRL2014). Fibroblast cells (1×105 cells/ml) were first
seeded in a 96-well plate in DMEM medium with 10% FBS and incubated at 37 ◦C in 5%
CO2 for 24 h. Cells were then treated with 1-monolaurin (3.9–2000 µM) and incubated
for an additional 24 h. Cell viability and morphological characteristics were observed
by fluorometric method and microscope, respectively (National Committee for Clinical
Laboratory Standards (NCCLS), 2002; O’Brien et al., 2000; Pasetto, Pardi & Murata, 2014).
The medium was then replaced with an inoculum of 5×103 to 2.5×103 CFU/ml C. albicans
(ATCC: SC5314) grown in DMEM without FBS. Fibroblast cells and C. albicans were
treated with 125 µM and 250 µM of 1-monolaurin. The plate was then incubated for 24 h.
The vehicle control tested was 1% ethanol while the positive control used was fluconazole
(32.2 µM). The distribution of dead and live fibroblast cells was examined using the
Viability/Cytotoxicity Assay Kit for Animal Live & Dead Cells (Biotium), which contains a
mixture of Calcein AM and EthDIII. Calcofluor white (Sigma) was used to stainC. albicans.
Fluorescent images of the double staining were captured using fluorescence microscopy
(EVOS fl microscope AMG, Bothell, WA, USA).
Co-culture model quantitative real-time PCR
All RNA was isolated from fibroblast cells and C. albicans. The fibroblast cell RNA and
C. albicans RNA were isolated and purified using the RNeasy MiniKit (Qiagen) and the
Ribopure Yeast Kit (Life Technology); respectively. A NanoPhotometer P360 (Implen) was
used to quantify the total RNA extracted. Reverse transcription of the RNA into cDNA was
carried out using iScript Advanced cDNA synthesis Kit for RT-qPCR (Biorad). Real-time
PCRwas conducted by using iQSYBRGreen Supermix (Biorad). TheC. albicansprimers for
the genes: Secreted Aspartyl Proteinases-1 (SAP-1), Phospholipase B-1 (PLB-1), and ACT-1
(housekeeping) were used (Nailis et al., 2010). ACT-1 was the gene used to normalize SAP-1
and PLB-1 genes expression. Based on a previous analysis using the RT2 Profiler PCR Array
Kit (Qiagen), the following host inflammatory cytokines genes were selected: IL1-alpha
(Qiagen Gene ID#: 3552; Qiagen, Hilden, Germany), IL1-beta (Qiagen Gene ID#: 3553;
Qiagen, Hilden, Germany), IL-8 (Qiagen Gene ID#: 3576; Qiagen, Hilden, Germany) and
GADPH (housekeeping) (Qiagen Gene ID#: 2597; Qiagen, Hilden, Germany). All data
from cytokines genes expression were normalized using the housekeeping gene GADPH.
PCR amplification was performed by using 20 µl reaction mix per well in a 96-well plate.
The reactions were conducted at 95 ◦C for 3 min, followed by 40 cycles of 15 s at 95 ◦C and
1 min at 60 ◦C. After PCR, the melting curve was obtained by incubating the samples at
increasing increments of 0.5 ◦C from 55 ◦C to 95 ◦C.
Statistical analysis
All data were expressed as means ± SEM using One-way Analysis of Variance (ANOVA),
followed by Dunnett test. The level of statistical significance was set at 0.05. Results were
considered significant if p-values were less than 0.05.
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Figure 1 Fungal load of biofilms treated with monolaurin and proteolytic enzymes activity level. Fun-
gal load of 1-monolaurin treated biofilms. *p < 0.05.
Table 1 Minimum inhibitory concentration (MIC) andminimum fungicidal concentration (MFC) of
1-monolaurin against Candida albicans.
Microorganism Monolaurin Fluconazole (positive control)
MIC (µM) MFC (µM) MIC (µM) MFC (µM)
Candida albicans 96901a 30 140 100 350
Candida albicans SC5314 25 100 10 80
Candida albicansMYA-2876 62.5–125 125–250 32.2 100




Susceptibility assay of 1-monolaurin showed antifungal activity against several strains of C.
albicans in planktonic form, including a fluconazole-resistant strain 96901 in comparison to
a standard antifungal agent, fluconazole (Table 1). The ranges of the minimum inhibitory
concentrations (MIC) and the minimum fungicidal concentrations (MFC) of monolaurin
against C. albicans MYA 8276 were compared to those of fluconazole. The MIC and MFC
of monolaurin were in the ranges of 62.5–125 µM and 125–250 µM, respectively, while
the MIC and MFC of fluconazole; were 32.2 µM and 100 µM, respectively. The MIC and
MFC of monolaurin against the fluconazole-resistant strain 96901 were found to be much
lower than those of fluconazole; 30 µM and 140 µM in comparison to the MIC and MFC
values of fluconazole of 100 µM and 350 µM, suggesting a strong antifungal potential
against fluconazole resistant strains. The MIC and MFC were established to identify the
concentrations needed to be applied to biofilms, which were in the range of ten times
the MIC.
In the biofilm assay, monolaurin in the concentrations of 1,250 µM and 2,500 µM,
equivalent to ten times and twenty times the upper range of MIC, were tested on C. albicans
Seleem et al. (2016), PeerJ, DOI 10.7717/peerj.2148 6/17
MYA 8276. Biofilm fungal load was expressed, as the Log of the colony formation unit
(CFU/ml). The results showed that treatments with 1-monolaurin at 1,250 µM and
2,500 µM had significant reduction (p < 0.05) in fungal load in comparison to the
vehicle control group (Fig. 1). Such findings indicate a strong potential antifungal activity
of monolaurin against C. albicans biofilms. It is important to note that 1-monolaurin
(3.9–2,500 µM) presented very minimal cytotoxicity to oral fibroblast cells, as illustrated
in Fig. 3. At the highest concentration of 2000 µM shown in Fig. 3, approximately 50%
of fibroblast cells were viable. Thus, the findings of the cytotoxicity assay indicated that
monolaurin in the concentrations of 3.9–2,500 µM did not result in 0% viability of cells.
Such findings confirmed the safety of monolaurin to oral cells, especially as it has been
approved by FDA as ‘‘GRAS’’ food additive substance.
Furthermore, we examined the enzymatic activities of C. albicans secreted proteolytic
enzymes, in the proteinase and phospholipase enzyme assays of biofilms, as such enzymes
are often associated with host tissue damage. Our goal was to identify any modulatory
effects of monolaurin on the enzyme activity level of C. albicans biofilms, which are
considered a major virulence factor contributing to the pathogenicity of C. albicans
biofilms. Collected supernatants of biofilms, which were treated with 1,250 µM and
2,500 µM of 1-monolaurin, showed no significant difference in either enzyme activity of
proteinases or phospholipases, when compared to the vehicle group (Fig. 2). Thus, there
was no reduction in enzyme activities, as expressed in Unit U/g of biofilm dry weight.
Such findings suggest no modulatory effects of monolaurin on either the proteinase or the
phospholipase enzymes.
In addition, co-culture models of immature biofilms of Candida coexisting with
fibroblasts exposed to monolaurin treatments of 62.5 µM and 125 µM were useful in
assessing the gene expression of Secreted Aspartyl Proteinases-1 (SAP-1) and Phospholipase
B-1 (PLB-1), two common genes that are often up-regulated in the presence of elevated
enzymatic activities of proteinases and phospholipases. Total RNA isolated from Candida
in the co-culture model was reverse transcribed into cDNA, which was used in real-
time PCR to quantify the gene expression of SAP-1 and PLB-1 normalized to a house
keeping gene, ACT-1. Similar to the results obtained from the biofilm proteinase and
phospholipase assays, there was no significant down-regulation of either SAP-1 or PLB-1 in
the groups treatedwith 62.5µMand 125µMofmonolaurin compared to the vehicle control
(Figs. 5A and 5B). Such findings confirm that there was no gene up-regulation of either
SAP-1 or PLB-1 in the immature C. albicans treated with monolaurin (62.5 µM and
125 µM).
The co-culturemodel was also helpful in visualizing a real model of immatureC. albicans
biofilm coexisting with fibroblast cells incubated with a tested antifungal treatment. Images
obtained by fluorescencemicroscopy allowed for a qualitative assessment of the distribution
of C. albicans (blue color) with respect to live (green color) and dead (red color) fibroblast
cells. Figure 4 showed fluorescent imaging of C. albicans coexisting with oral fibroblasts
in the presence of treatment of monolaurin (125 µM) in comparison fibroblasts and
C. albicans treated with vehicle control (1%) and positive control (fluconazole). Co-
culture model treated with 1-monolaurin (125 µM) (Fig. 4C) showed sparse and less
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Figure 2 Proteolytic enzymes activity of C. albicans after treatment with monolaurin. Secreted prote-
olytic enzymes activity of Candida albicans after treatment with 1-monolaurin; of (A) Proteinase, and (B)
Phospholipase enzymes.
dense accumulation of C. albicans (blue) compared to that treated with a vehicle control,
1% ethanol (Fig. 4A). It should be noted there were some dead fibroblast cells present
in the monolaurin treated models (Fig. 4C) since the cells in this model were considered
more sensitive to the agent being exposed to as opposed to cells examined in complex
clinical systems. Such observation of some dead cells detected in the co-culture model
of monolaurin are in agreement with the cytotoxicity reported for monolaurin, where
there was approximately 80% cell viability found at 125 µM of monolaurin. In general,
co-culture images of less dispersed C. albicans in the presence of monolaurin (Fig. 4C)
were comparable to those of the positive control group (fluconazole 32.2 µM) in Fig. 4B,
suggesting the efficacy of monolaurin in inhibiting the growth of C. albicans biofilms.
Another advantage of the co-culture model was that it provided invaluable information
on gene expression of host fibroblast cells infected with C. albicans and exposed to 1-
monolaurin treatments. Quantitative Real-time PCR assessed host gene expression of
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Figure 3 Cytotoxic effects of 1-monolaurinon on oral fibroblast cells.Note that monolaurin is recog-
nized as GRAS (Generally Recognized as Safe), as a food additive by the FDA (Food and Drug Administra-
tion), with topical doses of up to 100 mg/ml (Title 21, Code of Federal Regulations, Part 184).
Figure 4 Co-culture fluorescence microscopy of 1-monolaurin. (A) vehicle control (1% ethanol), (B) positive control (fluconazole), and (C) 1-
monolaurin (125 µM); stained with calcofluor white and cytotoxicity assay kit for animal Live/Dead cells (Blue: Candida albicans, Green: live fi-
broblast cells, and Red: dead fibroblast cells). Scale bar set at 1,000 um at 4×magnification power.
pro-inflammatory cytokines IL-1alpha, IL-1beta, and IL-8 in samples treated with of
1-monolaurin at MIC concentrations of 62.5 µM and 125 µM in comparison to the vehicle
control and the positive control groups. The goal of examining the cytokines expression
of the host was to test if there was any modulatory effects of monolaurin on the host’s
pro-inflammatory response during fungal infection. Figure 5C showed that at 125 µM
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Figure 5 Real-time quantitative gene expression of oral fibroblast cells infected by C. albicans after
1-monolaurin treatments at 62.5µMand 125µM concentrations in comparison to vehicle control and
positive control fluconazole (32.2µM). (A) SAP-1 (B) PLB-1 (C) IL-1α (D) IL-1β (E) IL-8.
of monolaurin, there was significant down-regulation of IL-1α compared to the vehicle
control group (p < 0.05). However, at a lower concentration of 62.5 µM, there was no
down-regulation of the IL-1α gene expression. Figure 5D showed that at 62.5µM, there was
a significant down-regulation of IL-1β gene expression in comparison to the vehicle control
group. However, there was no similar down-regulatory effect at a higher concentration
of 125 µM. The down-regulation of the pro-inflammatory cytokines gene expression of
IL-1α and IL-1β found with the treatments of monolaurin suggested that monolaurin was
capable of modulating the host inflammatory response although not in a dose dependent
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way, as in the case of IL-1β gene expression. IL-8 is another pro-inflammatory cytokine
known as a neutrophil chemotactic factor that induces migration of neutrophils and
phagocytosis at the infection site (Villar et al., 2005). We hypothesized that monolaurin
may affect the pro-inflammatory IL-8 cytokine in a down-regulatory manner similar to
the pro-inflammatory cytokines IL-1α and IL-1β. However, Fig. 5E showed a significant
up-regulation of IL-8 in the group treated with 62.5 µM of 1-monolaurin compared to
the vehicle control group, suggesting a strong neutrophilic chemotactic activity by the host
cells. These results were not dose dependent since at higher concentration of monolaurin
(125µM), there was a down-regulation of IL-8.However, the results of the down-regulation
of IL-8 by monolaurin at 125 µM were not statistically significant when compared to the
vehicle control group.
A possible explanation for the up-regulation of IL-8 noted in the samples treated with
62.5 µM of 1-monolaurin may be due to a negative feedback inhibition resulting from the
down-regulation of IL-1, as it was found that IL-1 induces IL-8 secretion in fibroblasts
(Kaplanski et al., 1994). Thus, by the decrease in the production of IL-1 as expected by the
down-regulation of IL-1 gene expression, there may be a negative feedback inhibition of
IL-8, resulting in the up-regulation of the gene expression of IL-8. It should be noted that
these cytokines were analyzed at an early or acute phase of fungal infection. It would be
interesting to assess such cytokines gene expression in a future model simulating a more
chronic phase of infection.
DISCUSSION
The primary goal of this study was to evaluate the antifungal effect of monolaurin against
C. albicans biofilms in vitro using a co-culture model. In addition, we investigated whether
monolaurin can alter the morphology of the biofilm community as well as the proteolytic
enzymatic activities of proteinases and phospholipases, which are considered critical
virulence factors associated with the pathogenicity ofC. albicans. Furthermore, we explored
the modulatory effects of monolaurin on the pro-inflammatory cytokines gene expression
of host fibroblast cells.
Susceptibility tests of monolaurin against C . albicans (MYA2876) showed inhibition of
fungal growth at anMIC range of 62.5–125µMwhileMFCwas in the range of 125–250µM,
which showed potential antifungal activity against this specific tested strain. In the biofilm
assay model, higher concentrations of monolaurin in the range of 10× and 20× the
concentrations of MIC, were used due to the tenacious nature of biofilms to be eradicated.
Biofilms treated with monolaurin showed significant reduction (p < 0.05) in the fungal
load, as illustrated by the decrease in Log (CFU/ml) in comparison to the control groups.
Similarly, the results obtained by fluorescence microscopy of the co-culture model
(Fig. 4C) showed a large decrease in viable C. albicans dispersed among oral fibroblasts
in the presence of 1-monolaurin (125 µM). It is important to note there were some
morphological changes in the oral fibroblast cells of the positive control group treated
with fluconazole (Fig. 4B) as well as those of the monolaurin treated group (Fig. 4C) in
comparison to the cells of the vehicle control group. While the overall density and the
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distribution of live fibroblasts (green color) may seem to be similar to the vehicle control,
there may be a shortened or a less elongated appearance of the fibroblasts in the 2 tested
groups, of monolaurin and fluconazole. A possible explanation is that a co-culture model
of fibroblasts coexisting with Candida and an antifungal agent may present an exaggerated,
sensitive effect on the morphology and distribution of fibroblast cells compared to cells
tested under clinically relevant conditions. Thus, the oral fibroblast cells in co-culturemodel
are considered to be ‘‘naked cells,’’ with more sensitivity to the treatments administered.
Therefore, the cells may show more signs of stress when exposed to an antifungal agent
compared to those of the vehicle control group.
As mentioned earlier, the safety of monolaurin, as a food additive and emulsifier
was recognized as GRAS (Generally Recognized as Safe) by the FDA (Food and Drug
Administration) for up to 100 mg/ml (Peterson & Schlievert, 2006). Not surprisingly, in our
cytotoxicity assay, 1-monolaurin showed no toxicity to oral fibroblast cells. In this study,
the lethal dosage of 1-monolaurin could not be calculated from a regression analysis since
no concentration of monolaurin has resulted in 0% cell viability. Thus, 1-monolaurin
showed no toxicity (up to 2,500 µM) to oral fibroblast cells and therefore was considered
safe to be studied in future in vivo investigations.
Amajor helpful analysis provided by the co-culturemodel was to study the inflammatory
cytokines of the host by quantification of a panel of inflammatory markers, such as
IL-1β, IL-6, IL-8, IL-10, and IL-17 (Arien, Vanham & Gali, 2011). Monolaurin 5% gel
was previously shown to inhibit innate inflammatory responses, as it prevented vaginal
SIV transmission in monkeys (Li et al., 2009). More specifically, glycerol monolaurate
has inhibitory activity against the production of MIP-3α and other pro-inflammatory
cytokines, and can inhibit mucosal signaling and block the inflammatory response toHIV-1
and SIV in vitro and in vivo (Li et al., 2009). In our current study, we tested gene expression
of pro-inflammatory cytokines, IL-1α and IL-1β after treatments with 1-monolaurin
at 62.5 µM and 125 µM. Our results showed a significant (p < 0.05) down-regulation
of IL-1α with the treatments of 1-monolaurin treatments at 125 µM (Fig. 5C), while
down-regulation of the IL-1β gene expression was achieved with monolaurin treatments at
62.5 µM. However, gene expression of IL-8 was not down-regulated in the biofilms treated
with monolaurin. It can be concluded that monolaurin can modulate host response by
down-regulating the gene expression of some of the pro-inflammatory cytokines, such as
IL-1α and IL-1β. Future research interests may involve studying other pro-inflammatory
as well as anti-inflammatory markers, such as IL-10, using the same co-culture model in
order to provide a more comprehensive analysis of the drug’s ability to modulate host
response and to determine if it can contribute to the anti-inflammatory mechanism in
mammalian cells.
The rationale for studying the activity of proteinases and phospholipases was that
such hydrolytic enzymes have been reported in the literature to be secreted by C. albicans
and are known to elicit host tissue damage (Lermann & Morschhauser, 2008). Thus, these
proteolytic enzymes are considered key virulence factors in the pathogenicity of C. albicans.
Our hypothesis was that if monolaurin were to have an antifungal activity against Candida,
it might do so by down-regulating such proteolytic enzymes. However, our findings did
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not confirm such hypothesis. It was found that treatments of monolaurin at 1,250 µM and
2,500 µM were not associated with a decrease in the enzymatic activity level of either the
proteinases or the phospholipases (Figs. 2A and 2B).
To confirm the findings on the proteolytic enzyme activities, the gene expression of
SAP1 (Secreted aspartyl protease) and phospholipase B (PLB) were assessed. During fungal
infections, there is generally a higher gene expression of SAPs (1-10), which is often
associated with hyphal formation and induction of rim101p, a transcription factor that
mediates the degradation of E-cadherin protein of the epithelial cell junction (Naglik et
al., 2008). In our study, the gene expression of SAP-1 was evaluated after application of
treatments of 1-monolaurin at concentrations of 62.5 µM and 125 µM and normalized by
the expression of ACT, a housekeeping gene. There was no statistical significance difference
in SAP-1 gene expression in comparison to the control groups (Fig. 5A). However, the role
of specific SAP genes to their attenuated phenotype is yet to be elucidated. In addition,
more studies would be helpful to explore the effects of monolaurin on the other members
of the SAPs family.
Similarly, phospholipases B1, B2, C and D of C. albicans play a significant role in the
invasion of the host tissue, as noted by their high gene expression during fungal infection
(Samaranayake et al., 2006). More specifically, phospholipase B (PLB) proteins were
shown to have hydrolytic activity, as they hydrolyze acyl ester bonds in phospholipids
and lysophospholipids and catalyze lysophospholipase-transacylase reactions (Theiss et
al., 2006). It was determined that the PLB multigene family of the opportunistic fungal
pathogen C . albicans encodes for CaPLB5, a putative secretory protein with a predicted
GPI-anchor attachment site. The ability of C. albicans to attach itself to the host tissue
is considered a key pathogenic characteristic and hence, genes encoding for attachment
proteins, such as PLB, may be potential virulence determinants (Theiss et al., 2006). In
this study, phospholipase enzyme activity was tested using both 1,250 µM and 2,500 µM
concentrations of 1-monolaurin, which showed no significant difference when compared
to the vehicle group (Fig. 2B). More studies are needed to elucidate the role of monolaurin
on the gene expression of the other phospholipases, such as phopspholipases B2, C, and D.
Thus, it can be concluded that monolaurin did not have a down-regulatory effect on the
gene expression of either SAP-1 or PLB-1 encoding for their respective enzymes produced
by C . albicans.
In conclusion, 1-monolaurin had potential antifungal activities against Candida
albicans both in susceptibility tests and biofilm assays. Furthermore, monolaurin had
immune-modulatory effects on the host cells, as indicated by its down-regulation of
pro-inflammatory cytokines gene expression of IL-1α and IL-1β. Future direction for
research may include understanding its impact on proteases activity on the cellular level
and whether there is a direct effect on attachment protein gene expression. Ultimately,
future studies may validate the efficacy of monolaurin in vivo, which may translate into its
potential clinical use to prevent and/or treat oral candidiasis.
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